

Impaired immune cell cytotoxicity in severe COVID-19

Journal of Clinical Investigation

130, 4694-4703

DOI: [10.1172/jci138554](https://doi.org/10.1172/jci138554)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients. <i>European Journal of Immunology</i> , 2020, 50, 2013-2024.	1.6	53
2	On the genetics and immunopathogenesis of COVID-19. <i>Clinical Immunology</i> , 2020, 220, 108591.	1.4	32
3	Continuous tracking of COVID-19 patients' immune status. <i>International Immunopharmacology</i> , 2020, 89, 107034.	1.7	32
4	Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e754-e763.	2.2	237
5	Lymphopenia during the COVID-19 infection: What it shows and what can be learned. <i>Immunology Letters</i> , 2020, 225, 31-32.	1.1	256
6	First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia. <i>Frontiers in Medicine</i> , 2020, 7, 596916.	1.2	5
7	Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions. <i>Clinical Infectious Diseases</i> , 2021, 72, e1130-e1143.	2.9	34
8	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. <i>Frontiers in Microbiology</i> , 2020, 11, 588409.	1.5	19
9	Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab. <i>Immunology Letters</i> , 2020, 228, 122-128.	1.1	14
10	COVID-19 and Obesity: Dangerous Liaisons. <i>Journal of Clinical Medicine</i> , 2020, 9, 2511.	1.0	107
11	A gendered magnifying glass on COVID-19. <i>Clinical and Molecular Allergy</i> , 2020, 18, 14.	0.8	19
12	T cell responses in patients with COVID-19. <i>Nature Reviews Immunology</i> , 2020, 20, 529-536.	10.6	706
13	SARS-CoV-2: characteristics and current advances in research. <i>Virology Journal</i> , 2020, 17, 117.	1.4	84
14	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. <i>International Immunopharmacology</i> , 2020, 88, 106980.	1.7	31
15	Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. <i>Cell Death and Disease</i> , 2020, 11, 921.	2.7	96
16	Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. <i>Immunology</i> , 2020, 161, 345-353.	2.0	68
17	Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. <i>European Respiratory Journal</i> , 2020, 56, 2003006.	3.1	172
18	Natural Killer Cell Dysfunction and Its Role in COVID-19. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6351.	1.8	129

#	ARTICLE	IF	CITATIONS
19	Characteristics, laboratories, and prognosis of severe COVID-19 in the Tokyo metropolitan area: A retrospective case series. PLoS ONE, 2020, 15, e0239644.	1.1	18
20	Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020. PLoS Pathogens, 2020, 16, e1008820.	2.1	21
21	No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19. Nanomedicine, 2020, 15, 2411-2427.	1.7	19
22	Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics. International Journal of Molecular Sciences, 2020, 21, 5793.	1.8	101
23	Natural killer cell immunotypes related to COVID-19 disease severity. Science Immunology, 2020, 5, .	5.6	344
24	Longitudinal Characteristics of T Cell Responses in Asymptomatic SARS-CoV-2 Infection. Virologica Sinica, 2020, 35, 838-841.	1.2	11
25	Can Natural Killer Cells Be a Principal Player in Anti-SARS-CoV-2 Immunity?. Frontiers in Immunology, 2020, 11, 586765.	2.2	28
26	Lymphocyte Changes in Severe COVID-19: Delayed Over-Activation of STING?. Frontiers in Immunology, 2020, 11, 607069.	2.2	38
27	Negative Clinical Evolution in COVID-19 Patients Is Frequently Accompanied With an Increased Proportion of Undifferentiated Th Cells and a Strong Underrepresentation of the Th1 Subset. Frontiers in Immunology, 2020, 11, 596553.	2.2	45
28	Threading the Pieces Together: Integrative Perspective on SARS-CoV-2. Pathogens, 2020, 9, 912.	1.2	6
29	Long-Term Existence of SARS-CoV-2 in COVID-19 Patients: Host Immunity, Viral Virulence, and Transmissibility. Virologica Sinica, 2020, 35, 793-802.	1.2	24
30	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2503-2541.	2.7	95
31	Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. Journal of Autoimmunity, 2020, 114, 102506.	3.0	248
32	Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. Frontiers in Immunology, 2020, 11, 1512.	2.2	126
33	Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids. Frontiers in Immunology, 2020, 11, 1445.	2.2	31
34	COVID-19 Associated Pulmonary Aspergillosis (CAPA)â€”From Immunology to Treatment. Journal of Fungi (Basel, Switzerland), 2020, 6, 91.	1.5	292
35	How could we forget immunometabolism in SARS-CoV2 infection or COVID-19?. International Reviews of Immunology, 2021, 40, 72-107.	1.5	33
36	Severe SARS-CoV-2 disease in the context of a NF-Î²B2 loss-of-function pathogenic variant. Journal of Allergy and Clinical Immunology, 2021, 147, 532-544.e1.	1.5	25

#	ARTICLE	IF	CITATIONS
37	Pathogenesis and directed therapy of 2019 novel coronavirus disease. <i>Journal of Medical Virology</i> , 2021, 93, 1320-1342.	2.5	40
38	Major reduction of NKT cells in patients with severe COVID-19 pneumonia. <i>Clinical Immunology</i> , 2021, 222, 108630.	1.4	39
39	T Cells: Warriors of SARS-CoV-2 Infection. <i>Trends in Immunology</i> , 2021, 42, 18-30.	2.9	142
40	The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. <i>Mucosal Immunology</i> , 2021, 14, 305-316.	2.7	173
41	Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19. <i>International Journal of Medical Sciences</i> , 2021, 18, 29-41.	1.1	24
42	PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19. <i>Immunity</i> , 2021, 54, 44-52.e3.	6.6	184
43	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. <i>EClinicalMedicine</i> , 2021, 31, 100689.	3.2	206
44	Herpes Zoster Duplex Unilateralis as a manifestation of severe lymphopenia in COVID19. <i>European Journal of Pain</i> , 2021, 25, 508-509.	1.4	4
45	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. <i>Leukemia</i> , 2021, 35, 1121-1133.	3.3	61
46	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection. <i>Clinical Microbiology Reviews</i> , 2021, 34, .	5.7	136
47	Role of the Immune Microenvironment in SARS-CoV-2 Infection. <i>Cell Transplantation</i> , 2021, 30, 096368972110106.	1.2	10
48	An Overview of Nucleic Acid Testing for the Novel Coronavirus SARS-CoV-2. <i>Frontiers in Medicine</i> , 2020, 7, 571709.	1.2	10
49	BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	108
50	A scoping review of the pathophysiology of COVID-19. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110480.	1.0	42
51	High levels of soluble CD25 in COVID-19 severity suggest a divergence between antiviral and pro-inflammatory T cell responses. <i>Clinical and Translational Immunology</i> , 2021, 10, e1251.	1.7	22
52	An immune-based biomarker signature is associated with mortality in COVID-19 patients. <i>JCI Insight</i> , 2021, 6, .	2.3	269
55	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. <i>Comparative Medicine</i> , 2021, 71, 342-358.	0.4	3
56	Haemophagocytic syndrome and COVID-19. <i>Clinical Rheumatology</i> , 2021, 40, 1233-1244.	1.0	53

#	ARTICLE	IF	CITATIONS
57	Immune response to COVID-19 infection: a double-edged sword. <i>Immunological Medicine</i> , 2021, 44, 187-196.	1.4	14
58	A review of the pathological mechanisms and clinical implications of coagulopathy in COVID-19. <i>Journal of Applied Hematology</i> , 2021, 12, 66.	0.1	0
59	Increased PD-L1 Expression May Be Associated With the Cytokine Storm and CD8+ T-Cell Exhaustion in Severe COVID-19. <i>Journal of Infectious Diseases</i> , 2021, 223, 1659-1660.	1.9	19
60	Immunological Characteristics of Non-Intensive Care Hospitalized COVID-19 Patients: A Preliminary Report. <i>Journal of Clinical Medicine</i> , 2021, 10, 849.	1.0	6
61	Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 629933.	1.1	43
62	Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. <i>Cells</i> , 2021, 10, 386.	1.8	125
63	Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF- κ B: A Systematic Review. <i>Viruses</i> , 2021, 13, 378.	1.5	14
64	T cell counts and IL-6 concentration in blood of North African COVID-19 patients are two independent prognostic factors for severe disease and death. <i>Journal of Leukocyte Biology</i> , 2021, 111, 269-281.	1.5	25
65	Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001549.	1.8	14
66	Reduced Expression of Autophagy Markers and Expansion of Myeloid-Derived Suppressor Cells Correlate With Poor T Cell Response in Severe COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 614599.	2.2	50
67	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 698-706.	0.5	37
68	Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab. <i>PLoS Pathogens</i> , 2021, 17, e1009243.	2.1	76
69	Immune checkpoint inhibition in COVID-19: risks and benefits. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1173-1179.	1.4	27
70	Implications of Laboratory Tests in Disease Grading and Death Risk Stratification of COVID-19: A Retrospective Study in Wuhan, China. <i>Frontiers in Medicine</i> , 2021, 8, 629296.	1.2	7
71	The Inflammatory Factors Associated with Disease Severity to Predict COVID-19 Progression. <i>Journal of Immunology</i> , 2021, 206, 1597-1608.	0.4	60
72	Is prognostic nutritional index a predictive marker for estimating all-cause in-hospital mortality in COVID-19 patients with cardiovascular risk factors?. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2021, 50, 307-312.	0.8	21
73	The Effect of Unconventional Cytokine Combinations on NK-Cell Responses to Viral Infection. <i>Frontiers in Immunology</i> , 2021, 12, 645850.	2.2	8
74	Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 63-85.	2.7	40

#	ARTICLE	IF	CITATIONS
75	Broad phenotypic alterations and potential dysfunction of lymphocytes in individuals clinically recovered from COVID-19. <i>Journal of Molecular Cell Biology</i> , 2021, 13, 197-209.	1.5	17
76	Immune memory in convalescent patients with asymptomatic or mild COVID-19. <i>Cell Discovery</i> , 2021, 7, 18.	3.1	35
77	Coronavirus disease 2019 (COVID-19) and autoimmunity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 5-30.	0.2	28
78	Longâ€œCOVID syndromeâ€œassociated brain fog and chemofog: Luteolin to the rescue. <i>BioFactors</i> , 2021, 47, 232-241.	2.6	128
79	COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients. <i>Journal of Infection</i> , 2021, 82, 329-338.	1.7	150
80	Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. <i>Cell Reports</i> , 2021, 34, 108863.	2.9	92
81	Regulation of the expression of proinflammatory cytokines induced by SARS-CoV-2. <i>World Journal of Clinical Cases</i> , 2021, 9, 1513-1523.	0.3	3
82	Immune Response Failure in Paucisymptomatic Long-Standing SARS-CoV-2 Spreaders. <i>Clinics and Practice</i> , 2021, 11, 151-161.	0.6	2
83	Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. <i>Nature Communications</i> , 2021, 12, 1386.	5.8	74
84	Do COVID-19 Infections Result in a Different Form of Secondary Hemophagocytic Lymphohistiocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2967.	1.8	10
88	The effect of azoximer bromide (PolyoxidoniumÂ®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. <i>Drugs in Context</i> , 2021, 10, 1-10.	1.0	3
89	T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 655934.	2.2	50
90	SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients. <i>American Journal of Transplantation</i> , 2021, 21, 2749-2761.	2.6	46
91	The role of extracorporeal membrane oxygenation in critically ill patients with COVID-19: a narrative review. <i>BMC Pulmonary Medicine</i> , 2021, 21, 116.	0.8	16
92	Increased Bâ€œcell activity with consumption of activated monocytes in severe COVIDâ€œ19 patients. <i>European Journal of Immunology</i> , 2021, 51, 1449-1460.	1.6	10
94	Endothelial cell, myeloid, and adaptive immune responses in SARSâ€œCoVâ€œ2 infection. <i>FASEB Journal</i> , 2021, 35, e21577.	0.2	13
95	Cytotoxicâ€œT-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformaticsâ€œframework. <i>Scientific Reports</i> , 2021, 11, 7653.	1.6	22
96	Gastrointestinal Microenvironment and the Gut-Lung Axis in the Immune Responses of Severe COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 647508.	1.6	9

#	ARTICLE	IF	CITATIONS
97	Edible and Herbal Plants for the Prevention and Management of COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 656103.	1.6	20
98	COVID-19 in Immunosuppressed Children. <i>Frontiers in Pediatrics</i> , 2021, 9, 629240.	0.9	30
99	Immunosuppression as a Hallmark of Critical COVID-19: Prospective Study. <i>Cells</i> , 2021, 10, 1293.	1.8	20
100	Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein. <i>Nature Communications</i> , 2021, 12, 2790.	5.8	26
101	Delivery Routes for COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 524.	2.1	37
102	Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 659018.	2.2	14
103	Adaptive immune responses to SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 1-8.	6.6	6
104	Role of Resveratrol in Prevention and Control of Cardiovascular Disorders and Cardiovascular Complications Related to COVID-19 Disease: Mode of Action and Approaches Explored to Increase Its Bioavailability. <i>Molecules</i> , 2021, 26, 2834.	1.7	14
105	Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: Potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19. <i>Cytokine</i> , 2021, 141, 155428.	1.4	62
107	Immune profiling of COVID-19: preliminary findings and implications for the pandemic. , 2021, 9, e002550.		15
108	Synergistic multiple early therapy (SMET) for inflammatory diseases with pathogenic autoinflammatory feedback circuits. <i>British Journal of Dermatology</i> , 2021, 185, 469-470.	1.4	0
109	Innate immune sensing of coronavirus and viral evasion strategies. <i>Experimental and Molecular Medicine</i> , 2021, 53, 723-736.	3.2	130
110	Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features. <i>Nature Communications</i> , 2021, 12, 2593.	5.8	94
111	Rationale for Randomized Clinical Trials Investigating the Potential of BCG Vaccination in Preventing COVID-19 Infection. <i>Bladder Cancer</i> , 2021, 7, 121-131.	0.2	0
112	A Virus-Specific Immune Rheostat in the Immunome of Patients Recovering From Mild COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 674279.	2.2	5
113	Severe T cell hyporeactivity in ventilated COVID-19 patients correlates with prolonged virus persistence and poor outcomes. <i>Nature Communications</i> , 2021, 12, 3006.	5.8	11
114	The SARS-CoV-2 protein ORF3a inhibits fusion of autophagosomes with lysosomes. <i>Cell Discovery</i> , 2021, 7, 31.	3.1	151
115	Hemophagocytic histiocytosis in severe SARS-CoV-2 infection: A bone marrow study. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1291-1301.	0.7	13

#	ARTICLE	IF	CITATIONS
116	SARS-CoV-2 and Plasma Hypercoagulability. Cellular and Molecular Bioengineering, 2021, 14, 513-522.	1.0	11
118	Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators. International Journal of Molecular Sciences, 2021, 22, 7017.	1.8	43
119	Immune characterization of a Colombian family cluster with SARS-CoV-2 infection. Biomedica, 2021, 41, 86-102.	0.3	2
120	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. Microorganisms, 2021, 9, 1389.	1.6	4
121	Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets. Frontiers in Immunology, 2021, 12, 680134.	2.2	54
123	Dynamics of host immune responses to SARS-CoV-2. World Journal of Clinical Cases, 2021, 9, 4480-4490.	0.3	0
124	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respiratory Medicine, the, 2021, 9, 622-642.	5.2	371
125	Role of IL-6&IL-27 Complex in Host Antiviral Immune Response. Journal of Immunology, 2021, 207, ji2100179.	0.4	2
126	Detection of SARS-CoV-2 RNA in serum is associated with increased mortality risk in hospitalized COVID-19 patients. Scientific Reports, 2021, 11, 13134.	1.6	27
129	Differential alterations in peripheral lymphocyte subsets in COVID-19 patients: upregulation of double-positive and double-negative T cells. Multidisciplinary Respiratory Medicine, 2021, 16, 758.	0.6	8
130	SARS-CoV-2 infection paralyzes cytotoxic and metabolic functions of the immune cells. Heliyon, 2021, 7, e07147.	1.4	15
131	The Quality of SARS-CoV-2&Specific T Cell Functions Differs in Patients with Mild/Moderate versus Severe Disease, and T Cells Expressing Coinhibitory Receptors Are Highly Activated. Journal of Immunology, 2021, 207, 1099-1111.	0.4	34
132	Single-Cell Transcriptomic Profiling of MAIT Cells in Patients With COVID-19. Frontiers in Immunology, 2021, 12, 700152.	2.2	22
133	Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. Oxford Open Immunology, 2021, 2, .	1.2	7
134	Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence of Different Serum Supplements. Biomolecules, 2021, 11, 1066.	1.8	2
135	Abnormality in the NK-cell population is prolonged in severe COVID-19 patients. Journal of Allergy and Clinical Immunology, 2021, 148, 996-1006.e18.	1.5	38
136	Innate lymphoid cells (ILC) in SARS-CoV-2 infection. Molecular Aspects of Medicine, 2021, 80, 101008.	2.7	10
137	Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. Biomedicine and Pharmacotherapy, 2021, 140, 111785.	2.5	14

#	ARTICLE	IF	CITATIONS
138	Convalescent COVID-19 Patients Without Comorbidities Display Similar Immunophenotypes Over Time Despite Divergent Disease Severities. <i>Frontiers in Immunology</i> , 2021, 12, 601080.	2.2	7
139	Activation or exhaustion of CD8+ T cells in patients with COVID-19. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2325-2333.	4.8	106
140	Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis – Author’s reply. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1177-1178.	2.8	1
141	Autoimmunity and COVID-19 – The microbiotal connection. <i>Autoimmunity Reviews</i> , 2021, 20, 102865.	2.5	25
142	High-dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS-CoV-2 infection: A case-based review of the literature (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1182.	0.8	10
143	Different T cell related immunological profiles in COVID-19 patients compared to healthy controls. <i>International Immunopharmacology</i> , 2021, 97, 107828.	1.7	21
144	Ways to Address Perinatal Mast Cell Activation and Focal Brain Inflammation, including Response to SARS-CoV-2, in Autism Spectrum Disorder. <i>Journal of Personalized Medicine</i> , 2021, 11, 860.	1.1	15
145	Immunological and inflammatory profiles during acute and convalescent phases of severe/critically ill COVID-19 patients. <i>International Immunopharmacology</i> , 2021, 97, 107685.	1.7	22
146	Cytokine Storms in the Course of COVID-19 and Haemophagocytic Lymphohistiocytosis in Pregnant and Postpartum Women. <i>Biomolecules</i> , 2021, 11, 1202.	1.8	13
147	An Overview on the Epidemiology and Immunology of COVID-19. <i>Journal of Infection and Public Health</i> , 2021, 14, 1284-1298.	1.9	13
148	TREC/KREC Levels in Young COVID-19 Patients. <i>Diagnostics</i> , 2021, 11, 1486.	1.3	8
149	Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. <i>American Journal of Hematology</i> , 2021, 96, E408-E410.	2.0	30
150	Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. <i>Science Immunology</i> , 2021, 6, .	5.6	20
151	Immune System Disequilibrium – Neutrophils, Their Extracellular Traps, and COVID-19-Induced Sepsis. <i>Frontiers in Medicine</i> , 2021, 8, 711397.	1.2	6
152	Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice. <i>Human Immunology</i> , 2022, 83, 86-98.	1.2	37
153	Mast cells: Therapeutic targets for COVID-19 and beyond. <i>IUBMB Life</i> , 2021, 73, 1278-1292.	1.5	14
154	Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19. <i>Cell Reports</i> , 2021, 37, 109798.	2.9	28
155	What we know and still ignore on COVID-19 immune pathogenesis and a proposal based on the experience of allergic disorders. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1114-1128.	2.7	6

#	ARTICLE	IF	CITATIONS
156	Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls. <i>Rheumatology International</i> , 2022, 42, 457-467.	1.5	4
157	Manifestations and mechanisms of central nervous system damage caused by SARS-CoV-2. <i>Brain Research Bulletin</i> , 2021, 177, 155-163.	1.4	12
158	Peptides Derived From S and N Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Induce T Cell Responses: A Proof of Concept for T Cell Vaccines. <i>Frontiers in Microbiology</i> , 2021, 12, 732450.	1.5	10
159	Pattern Recognition Proteins: First Line of Defense Against Coronaviruses. <i>Frontiers in Immunology</i> , 2021, 12, 652252.	2.2	13
160	Perforin, COVID-19 and a possible pathogenic auto-inflammatory feedback loop. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13102.	1.3	11
162	SARS-CoV-2-specific T cells in infection and vaccination. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2307-2312.	4.8	131
163	Multimiomics: unraveling the panoramic landscapes of SARS-CoV-2 infection. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2313-2324.	4.8	31
164	SARS-CoV-2, COVID-19 and the aging immune system. <i>Nature Aging</i> , 2021, 1, 769-782.	5.3	208
165	Mild and Asymptomatic COVID-19 Convalescents Present Long-Term Endotype of Immunosuppression Associated With Neutrophil Subsets Possessing Regulatory Functions. <i>Frontiers in Immunology</i> , 2021, 12, 748097.	2.2	22
166	Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	9
167	Increased Blood Monocytic Myeloid Derived Suppressor Cells but Low Regulatory T Lymphocytes in Patients with Mild COVID-19. <i>Viral Immunology</i> , 2021, 34, 639-645.	0.6	13
168	Evaluation of hematological indices in terms of COVID-19 related mortality and ICU admission. <i>Journal of Health Sciences and Medicine</i> , 2021, 4, 666-669.	0.0	7
169	Lymphopenia: A useful predictor of COVID-19 disease severity and mortality. <i>Pakistan Journal of Medical Sciences</i> , 2021, 37, 1984-1988.	0.3	19
170	Computational simulations to dissect the cell immune response dynamics for severe and critical cases of SARS-CoV-2 infection. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 211, 106412.	2.6	14
171	Prompt Reduction in CRP, IL-6, IFN- γ , IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 734838.	1.2	13
172	SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals. <i>Immune Network</i> , 2021, 21, e2.	1.6	12
173	T cell response to SARS-CoV-2 infection in humans: A systematic review. <i>PLoS ONE</i> , 2021, 16, e0245532.	1.1	228
174	SARS-CoV-2-Associated T-Cell Responses in the Presence of Humoral Immunodeficiency. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 195-209.	0.9	39

#	ARTICLE	IF	CITATIONS
175	The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	59
176	Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients. <i>Experimental Hematology and Oncology</i> , 2021, 10, 5.	2.0	37
177	T cell phenotypes in COVID-19 - a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqaa007.	1.2	19
192	SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition. <i>Journal of Clinical Investigation</i> , 2020, 130, 6477-6489.	3.9	181
193	Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 6656-6667.	3.9	101
194	The immune system view of the coronavirus SARS-CoV-2. <i>Biology Direct</i> , 2020, 15, 30.	1.9	19
196	Coronavirus disease 2019 in critically ill patients: can we re-program the immune system? A primer for Intensivists. <i>Minerva Anestesiologica</i> , 2020, 86, 1214-1233.	0.6	1
197	The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review. <i>PeerJ</i> , 2020, 8, e10322.	0.9	47
198	Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2pos subjects. <i>Cell Research</i> , 2021, 31, 1148-1162.	5.7	12
199	Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. <i>Seminars in Immunology</i> , 2021, 55, 101508.	2.7	37
200	Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 2132.	1.5	29
201	Basophils and Mast Cells in COVID-19 Pathogenesis. <i>Cells</i> , 2021, 10, 2754.	1.8	40
202	Untimely TGF β 2 responses in COVID-19 limit antiviral functions of NK cells. <i>Nature</i> , 2021, 600, 295-301.	13.7	146
203	Genetic and phenotypic analysis of the causal relationship between aging and COVID-19. <i>Communications Medicine</i> , 2021, 1, .	1.9	19
204	Systematic investigation of a potential epidemiological and genetic association between male androgenetic alopecia and COVID-19. <i>Skin Health and Disease</i> , 2021, 1, e72.	0.7	3
205	Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*. <i>Critical Care Medicine</i> , 2022, 50, 398-409.	0.4	27
206	Anti-VEGF agents: As appealing targets in the setting of COVID-19 treatment in critically ill patients. <i>International Immunopharmacology</i> , 2021, 101, 108257.	1.7	18
210	Myeloid cells in COVID-19 microenvironment. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 372.	7.1	14

#	ARTICLE	IF	CITATIONS
211	Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. <i>Cell Death and Disease</i> , 2021, 12, 1019.	2.7	3
212	The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes. <i>Frontiers in Immunology</i> , 2021, 12, 697622.	2.2	10
213	Gamma Delta T Cells and Their Involvement in COVID-19 Virus Infections. <i>Frontiers in Immunology</i> , 2021, 12, 741218.	2.2	21
214	Differential dynamics of peripheral immune responses to acute SARS-CoV-2 infection in older adults. <i>Nature Aging</i> , 2021, 1, 1038-1052.	5.3	10
215	The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus. <i>Journal of Virology</i> , 2022, 96, JV10096421.	1.5	84
216	Single-cell immunophenotyping of the fetal immune response to maternal SARS-CoV-2 infection in late gestation. <i>Pediatric Research</i> , 2022, 91, 1090-1098.	1.1	14
219	Overview of the immune response against SARS-CoV-2. , 2022, , 95-113.		0
220	Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy. <i>Vaccines</i> , 2021, 9, 1392.	2.1	7
221	NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19. <i>Cells</i> , 2021, 10, 3182.	1.8	19
222	Jinhua Qinggan granule, a Chinese herbal medicine against COVID-19, induces rapid changes in the neutrophil/lymphocyte ratio and plasma levels of IL-6 and IFN- γ : An open-label, single-arm pilot study. <i>World Academy of Sciences Journal</i> , 2021, 4, .	0.4	7
223	Clinical Relevance of Elevated Soluble ST2, HSP27 and 20S Proteasome at Hospital Admission in Patients with COVID-19. <i>Biology</i> , 2021, 10, 1186.	1.3	10
224	Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe Individuals. <i>Frontiers in Immunology</i> , 2021, 12, 710217.	2.2	8
225	Corona Virus Disease 2019 (COVID-19) as a System-Level Infectious Disease With Distinct Sex Disparities. <i>Frontiers in Immunology</i> , 2021, 12, 778913.	2.2	5
226	Research on SARS-COV-2 pandemic: a narrative review focused on the Italian contribution. <i>Journal of Anesthesia, Analgesia and Critical Care</i> , 2021, 1, .	0.5	0
227	Prognostic Nutritional Index and CRP, age, platelet count, albumin level score in predicting mortality and intensive care unit admission for COVID-19. <i>Biomarkers in Medicine</i> , 2021, 15, 1733-1740.	0.6	7
228	Hypertension and its management in COVID-19 patients: The assorted view. <i>International Journal of Cardiology Cardiovascular Risk and Prevention</i> , 2021, 11, 200121.	0.4	31
229	NK cells at the crossroads in COVID-19: a question of timing. <i>Ciencia, Tecnología Y Salud</i> , 2020, 7, 309-324.	0.0	1
230	Lesion types, pathogenesis, pathological manifestations, and imaging findings of cardiovascular complications induced by coronavirus disease 2019: Current status. <i>Radiology of Infectious Diseases</i> , 2021, 8, 45.	2.4	0

#	ARTICLE	IF	CITATIONS
231	Genes implicados en la gravedad de la infección por SARS-cov- 2. Revista Vive, 2021, 4, 305-318.	0.1	0
232	Single-cell immunology of SARS-CoV-2 infection. Nature Biotechnology, 2022, 40, 30-41.	9.4	78
233	Dynamics of Peripheral Blood T-lymphocytes Have Predictive Values for the Clinical Outcome of COVID-19 Patients in Intensive Care Unit. BMC Clinical Pathology, 2022, 15, 2632010X2110728.	0.7	0
234	Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?. Molecular Neurobiology, 2022, 59, 1850-1861.	1.9	76
235	COVID-19 Pandemic and Periodontal Practice: The Immunological, Clinical, and Economic Points of View. BioMed Research International, 2022, 2022, 1-10.	0.9	4
236	Comprehensive Immune Profiling Reveals CD56+ Monocytes and CD31+ Endothelial Cells Are Increased in Severe COVID-19 Disease. Journal of Immunology, 2022, 208, 685-696.	0.4	14
238	Are NKT cells a useful predictor of COVID-19 severity?. Immunity, 2022, 55, 185-187.	6.6	9
239	Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection. Inflammopharmacology, 2022, 30, 23-49.	1.9	8
241	Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2. Journal of General Virology, 2022, 103, .	1.3	2
242	T cell apoptosis characterizes severe Covid-19 disease. Cell Death and Differentiation, 2022, 29, 1486-1499.	5.0	90
243	Platelets modulate CD4 ⁺ T cell function in COVID-19 through a PD-1 dependent mechanism. British Journal of Haematology, 2022, 197, 283-292.	1.2	5
245	Advances in clinical outcomes: What we have learned during the COVID-19 pandemic. Journal of Allergy and Clinical Immunology, 2022, 149, 569-578.	1.5	3
246	New Discovery of Myeloid-Derived Suppressor Cell's Tale on Viral Infection and COVID-19. Frontiers in Immunology, 2022, 13, 842535.	2.2	7
248	Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host. International Immunopharmacology, 2022, 105, 108531.	1.7	1
249	Thrombocytopenia in COVID-19 and vaccine-induced thrombotic thrombocytopenia. International Journal of Molecular Medicine, 2022, 49, .	1.8	4
250	The Female-Predominant Persistent Immune Dysregulation of the Post-COVID Syndrome. Mayo Clinic Proceedings, 2022, 97, 454-464.	1.4	52
251	The crucial role of prolactin-lactogenic hormone in Covid-19. Molecular and Cellular Biochemistry, 2022, 477, 1381-1392.	1.4	27
252	Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment. Transfusion, 2022, 62, 570-583.	0.8	8

#	ARTICLE	IF	CITATIONS
253	The Journal of Clinical Investigation in the time of COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	2
254	Perspective of HLA-G Induced Immunosuppression in SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 788769.	2.2	18
255	Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 438.	7.1	29
256	SARS-COV-2 Induce Pulmonary Injury from Basic to Clinical Research. <i>World Journal of Cardiovascular Diseases</i> , 2022, 12, 168-190.	0.0	0
257	COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study. <i>Leukemia and Lymphoma</i> , 2022, 63, 1607-1616.	0.6	4
258	Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. <i>Nature Communications</i> , 2022, 13, 946.	5.8	30
259	SARS-CoV-2 Immunization Orchestrates the Amplification of IFN β -Producing T Cell and NK Cell Persistence. <i>Frontiers in Immunology</i> , 2022, 13, 798813.	2.2	9
261	Innate Immune Response in SARS-CoV-2 Infection. <i>Microorganisms</i> , 2022, 10, 501.	1.6	13
262	CD4 ⁺ T-Cell Dysfunction in Severe COVID-19 Disease Is Tumor Necrosis Factor- α /Tumor Necrosis Factor Receptor 1-Dependent. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1403-1418.	2.5	21
263	SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells. <i>Cell Reports</i> , 2022, 38, 110503.	2.9	31
264	Distinct Expression Patterns of Interleukin-22 Receptor 1 on Blood Hematopoietic Cells in SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2022, 13, 769839.	2.2	10
265	Effectiveness of Tocilizumab in hospitalized moderate-to-severe COVID-19 patients: a real life study. <i>Panminerva Medica</i> , 2022, , .	0.2	1
266	Association between inflammatory cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19. <i>Immunity and Ageing</i> , 2022, 19, 12.	1.8	23
267	SARS-CoV-2 Associated Immune Dysregulation and COVID-Associated Pulmonary Aspergilliosis (CAPA): A Cautionary Tale. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3228.	1.8	3
268	Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. <i>Immunity, Inflammation and Disease</i> , 2022, 10, e595.	1.3	6
269	Hematopoietic responses to SARS-CoV-2 infection. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 187.	2.4	29
270	Metabolic programs tailor T cell immunity in viral infection, cancer, and aging. <i>Cell Metabolism</i> , 2022, 34, 378-395.	7.2	41
271	Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19. <i>Drugs in Context</i> , 2022, 11, 1-15.	1.0	0

#	ARTICLE	IF	CITATIONS
272	SARS-CoV-2-Specific and Functional Cytotoxic CD8 Cells in Primary Antibody Deficiency: Natural Infection and Response to Vaccine. <i>Journal of Clinical Immunology</i> , 2022, 42, 914-922.	2.0	16
273	CHARM: COVID-19 Health Action Response for Marines—Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test. <i>PLoS ONE</i> , 2022, 17, e0266691.	1.1	1
274	Apparent Association of Insulin With Interleukin-6 (IL-6) in Severe COVID-19 Patients Having Chronic Disease Comorbidities. <i>Cureus</i> , 2022, 14, e23790.	0.2	2
275	Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes. <i>Mechanisms of Ageing and Development</i> , 2022, 204, 111667.	2.2	12
278	Administration of HeberFERON in Patients with Persistent Oropharyngeal SARS-CoV-2 Wuhan/D614G Strain Viral Shedding. <i>Journal of Biomedical Research & Environmental Sciences</i> , 2021, 2, 1253-1266.	0.1	0
279	Expansion of CD56dimCD16neg NK Cell Subset and Increased Inhibitory KIRs in Hospitalized COVID-19 Patients. <i>Viruses</i> , 2022, 14, 46.	1.5	12
280	Combination of cycle threshold time, absolute lymphocyte count and neutrophil:lymphocyte ratio is predictive of hypoxia in patients with SARS-CoV-2 infection. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2022, 116, 628-635.	0.7	5
281	Role of the cellular immunity in the formation of the immune response in coronavirus infections. <i>Medical Immunology (Russia)</i> , 2021, 23, 1229-1238.	0.1	3
282	Severe Type of COVID-19: Pathogenesis, Warning Indicators and Treatment. <i>Chinese Journal of Integrative Medicine</i> , 2022, 28, 3-11.	0.7	5
283	An update on host immunity correlates and prospects of re-infection in COVID-19. <i>International Reviews of Immunology</i> , 2022, 41, 367-392.	1.5	9
285	Early Response of CD8+ T Cells in COVID-19 Patients. <i>Journal of Personalized Medicine</i> , 2021, 11, 1291.	1.1	17
286	Binding of phosphatidylserine-positive microparticles by PBMCs classifies disease severity in COVID-19 patients. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12173.	5.5	19
287	COVID-19 infection as a new risk factor for penile Mondor disease. <i>BMC Urology</i> , 2022, 22, 57.	0.6	5
288	Ad26.COV2.S prevents upregulation of SARS-CoV-2 induced pathways of inflammation and thrombosis in hamsters and rhesus macaques. <i>PLoS Pathogens</i> , 2022, 18, e1009990.	2.1	4
291	Dynamic response landscape of immune cells identified immune dysfunction which predicts disease progression in COVID-19 infected patients. <i>International Journal of Biological Sciences</i> , 2022, 18, 3066-3081.	2.6	1
293	Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2. <i>Frontiers in Immunology</i> , 2022, 13, 848335.	2.2	2
294	Exploring the Utility of NK Cells in COVID-19. <i>Biomedicines</i> , 2022, 10, 1002.	1.4	12
295	Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4894.	1.8	17

#	ARTICLE	IF	CITATIONS
296	Immunouniverse of SARS-CoV-2. <i>Immunological Medicine</i> , 2022, 45, 186-224.	1.4	8
297	Adaptive Immune Responses and Immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	39
298	From COVID-19 to Sarcoidosis: How Similar Are These Two Diseases?. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
299	In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection. <i>Scientific Reports</i> , 2022, 12, 7237.	1.6	2
300	Tocilizumab Accelerates Recovery in Patients With Severe COVID-19 Pneumonia on Venovenous Extracorporeal Membrane Oxygenation. <i>ASAIO Journal</i> , 2022, 68, 1010-1016.	0.9	3
301	Immune response in COVID-19: what is next?. <i>Cell Death and Differentiation</i> , 2022, 29, 1107-1122.	5.0	69
302	Differences in Characteristics of T-Cell Immunity to SARS-CoV-2 in Clinically Healthy Subjects. <i>Bulletin of Experimental Biology and Medicine</i> , 2022, 173, 133-138.	0.3	2
303	Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L14-L26.	1.3	15
304	Immune profile of children diagnosed with multisystem inflammatory syndrome associated with SARS-CoV-2 infection (MIS-C). <i>Central-European Journal of Immunology</i> , 0, , .	0.4	0
305	Histopathological examination of the placenta after delivery in pregnant women with COVID-19. <i>Journal of Health Sciences and Medicine</i> , 2022, 5, 868-874.	0.0	2
306	Characteristics of Natural Killer (NK) Cell and T Lymphocyte in COVID-19 patients in Surabaya, Indonesia. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 2198-2203.	0.2	4
307	Effective Natural Killer Cell Degranulation Is an Essential Key in COVID-19 Evolution. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6577.	1.8	3
308	Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
309	Connecting the dots between inflammatory cascades of obesity and COVID-19 in light of mortal consequencesâ€”a review. <i>Environmental Science and Pollution Research</i> , 2022, 29, 57040-57053.	2.7	3
310	What Inhibits Natural Killersâ€™ Performance in Tumour. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7030.	1.8	2
311	Immune Cells Profiles In The Peripheral Blood Of Patients With Moderate To Severe COVID-19 And Healthy Subjects With and Without Vaccination With The Pfizer-BioNTech mRNA Vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
312	NK cell dysfunction is linked with disease severity in SARSâ€“CoVâ€“2 patients. <i>Cell Biochemistry and Function</i> , 2022, 40, 559-568.	1.4	5
313	Current status and prospects of IL-6â€“targeting therapy. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 575-592.	1.3	10

#	ARTICLE	IF	CITATIONS
314	Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring Hospitalization. <i>Journal of Clinical Immunology</i> , 2022, 42, 1379-1391.	2.0	18
315	The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update. <i>Journal of Medical Virology</i> , 2022, 94, 5128-5148.	2.5	12
316	Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113368.	2.5	6
317	Identification of lymphocyte subgroups with flow cytometry in COVID-19 patients. <i>Journal of Health Sciences and Medicine</i> , 2022, 5, 1183-1189.	0.0	0
319	Acute kidney injury associated to COVID-19 leads to a strong unbalance of circulant immune mediators. <i>Cytokine</i> , 2022, 157, 155974.	1.4	12
320	Lymphocyte Population Changes at Two Time Points during the Acute Period of COVID-19 Infection. <i>Journal of Clinical Medicine</i> , 2022, 11, 4306.	1.0	6
321	Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants. <i>Vaccines</i> , 2022, 10, 1208.	2.1	5
322	Cellular heterogeneity in disease severity and clinical outcome: Granular understanding of immune response is key. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
324	SARS-CoV-2 and Immunity: Natural Infection Compared with Vaccination. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8982.	1.8	4
325	Where do T cell subsets stand in SARS-CoV-2 infection: an update. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	5
326	Evaluation of Hematologic Parameters in Patients with COVID-19 Following Mesenchymal Stem Cell Therapy. <i>DNA and Cell Biology</i> , 2022, 41, 768-777.	0.9	0
327	Obesity and metabolic dysfunction drive sex-associated differential disease profiles in hACE2-mice challenged with SARS-CoV-2. <i>IScience</i> , 2022, 25, 105038.	1.9	9
328	Pyroptotic cell death in SARS-CoV-2 infection: revealing its roles during the immunopathogenesis of COVID-19. <i>International Journal of Biological Sciences</i> , 2022, 18, 5827-5848.	2.6	15
329	Heterogenous CD8+ T Cell Maturation and "Polarization"™ in Acute and Convalescent COVID-19 Patients. <i>Viruses</i> , 2022, 14, 1906.	1.5	16
330	Neutrophil-Lymphocyte Ratio Predicting Case Severity in SARS-CoV-2 Infection: A Review. <i>Cureus</i> , 2022, , .	0.2	0
331	Effector memory T cell subset $CD45^{RA+} CCR7^{-} CD27^{-} CD28^{-}$ EM3 increases in direct proportion to the disease severity of COVID-19. <i>Scandinavian Journal of Immunology</i> , 0, , .	1.3	0
332	SARS-CoV-2 and Endothelial Cells: Vascular Changes, Intussusceptive Microvascular Growth and Novel Therapeutic Windows. <i>Biomedicines</i> , 2022, 10, 2242.	1.4	6
333	IL411 binds to TMPRSS13 and competes with SARS-CoV-2 spike. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1

#	ARTICLE	IF	CITATIONS
334	Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 993-1004.	1.5	14
335	Genetics of <scp>COVID</scp>â€19 and myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1838-1857.	1.7	2
336	Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
337	The function of myeloid-derived suppressor cells in COVID-19 lymphopenia. <i>International Immunopharmacology</i> , 2022, 112, 109277.	1.7	3
338	Clinical effect of early administration of tocilizumab following the initiation of corticosteroid therapy for patients with COVID-19. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1639-1644.	0.8	1
339	Generation of Cytotoxic T Cells and Dysfunctional CD8 T Cells in Severe COVID-19 Patients. <i>Cells</i> , 2022, 11, 3359.	1.8	4
340	Effect of vitamin D3 supplementation on cellular immunity and inflammatory markers in COVID-19 patients admitted to the ICU. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
342	Prognostic peripheral blood biomarkers at ICU admission predict COVID-19 clinical outcomes. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
343	Age-dependent NK cell dysfunctions in severe COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
344	High activation levels maintained in receptorâ€binding domainâ€specific memory B cells in people with severe coronavirus disease 2019. <i>Immunology and Cell Biology</i> , 2023, 101, 142-155.	1.0	1
345	Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19. <i>Clinical Immunology</i> , 2023, 246, 109209.	1.4	14
346	Immunosenescence and inflamm-ageing in COVID-19. <i>Ageing Research Reviews</i> , 2023, 84, 101818.	5.0	18
347	Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
348	Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
349	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
350	The role of <scp>HMGB1</scp> in <scp>COVIDâ€19â€induced</scp> cytokine storm and its potential therapeutic targets: A review. <i>Immunology</i> , 2023, 169, 117-131.	2.0	8
351	Current Developments in the Preclinical and Clinical use of Natural Killer T cells. <i>BioDrugs</i> , 2023, 37, 57-71.	2.2	4
352	Adaptive immune system in severe COVID-19 patients in the first week of illness: A pilot study. <i>European Journal of Microbiology and Immunology</i> , 2023, , .	1.5	0

#	ARTICLE	IF	CITATIONS
353	Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
354	Natural killer cells for antiviral therapy. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	3
355	CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. <i>Cell Reports Medicine</i> , 2023, 4, 100878.	3.3	24
357	COVID-19'a Ba'yt Sitokin F'tnas'nda Anakinra ve Tosilizumab Tedavilerinin Kar'la'tr'Imas' , 0, , .		0
358	The role of T cell immunity in COVID-19. , 2023, , 129-140.		0
359	Immune responses in mildly versus critically ill COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	18
360	Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. , 2023, , 237-262.		0
361	Anti-SARS-CoV-2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients. <i>Clinical Respiratory Journal</i> , 0, , .	0.6	0
362	Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV. <i>EBioMedicine</i> , 2023, 90, 104538.	2.7	1
364	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
365	Characteristics and Potential Roles of Natural Killer Cells During SARS-CoV-2 Infection. <i>Infectious Diseases & Immunity</i> , 2023, 3, 29-35.	0.2	0
367	Functionality of immune cells in COVID-19 infection: development of cell-based therapeutics. <i>BioImpacts</i> , 0, , .	0.7	0
368	Role of the immune system in COVID-19 pathomorphogenesis. <i>Genes and Cells</i> , 2020, 15, 75-87.	0.2	0
369	Comparison of T Lymphocyte Subsets and Natural Killer Lymphocytes in Moderate Versus Severe COVID-19 Patients. <i>Viral Immunology</i> , 0, , .	0.6	0
370	NK cells in COVID-19"from disease to vaccination. <i>Journal of Leukocyte Biology</i> , 2023, 114, 507-512.	1.5	2
371	Hemophagocytic Syndrome and COVID-19: A Comprehensive Review. <i>Cureus</i> , 2023, , .	0.2	0
372	SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model. <i>Antiviral Research</i> , 2023, 212, 105580.	1.9	2
373	Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination. <i>Scientific Reports</i> , 2023, 13, .	1.6	0

#	ARTICLE	IF	CITATIONS
374	Role of gut microbiota in infectious and inflammatory diseases. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	12
375	Higher proinflammatory responses possibly contributing to suppressed cytotoxicity in patients with COVID-19 associated mucormycosis. <i>Immunobiology</i> , 2023, 228, 152384.	0.8	2
376	Distinctive Dynamics and Functions of the CD4+CD25+FOXP3+ Regulatory T Cell Population in Patients with Severe and Mild COVID-19. <i>Journal of Immunology</i> , 2023, 210, 1687-1699.	0.4	4
377	FEMALE HEALTH AMIDST THE COVID-19 PANDEMIC. , 2023, 2, 9-15.		0
378	The liver-to-spleen ratio is a risk factor predicting oxygen demand in COVID-19 patients. , 2023, , .		0
403	T cell responses to SARS-COV-2. <i>Progress in Molecular Biology and Translational Science</i> , 2023, , .	0.9	0
411	Adjuvante Behandlung bei COVID-19 und Sepsis â was haben wir gelernt?. <i>Medizinische Klinik - Intensivmedizin Und Notfallmedizin</i> , 0, , .	0.4	1
414	COVID-19 therapy directed against pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2. , 2024, , 2697-2726.		0
424	Evaluation of TIM-3 gene expression in a patients with COVID-19. <i>AIP Conference Proceedings</i> , 2024, , .	0.3	0